BOSTON (TheStreet) -- This week's Biotech Stock Mailbag is open for business.
Oke M. writes, "Is Aethlon Medical (AEMD) raising money in a similar way to the Lincoln Park Financial vulture financing scheme used by Galena Biopharma (GALE) ? Is the money coming from an institutional investor? And why are they buying the shares at a price way below the current market price and guaranteed this very price for five years? How would this affect the overall price of Aethlon shares on the open market?"
Someone on Twitter this week (I don't remember who) made a snarky but accurate observation about Aethlon: If a disease appears on the front page of a newspaper, Aethlon will claim to have a cure in short order. Ouch!
Aethlon's disease cure-all is called the Hemopurifier, which as the name suggests, purifies a patient's blood by sopping up viruses and other nasty disease particles. Supposedly, I've been referring to the experimental, unapproved medical device as the plastic miracle cylinder because there's hardly a disease it can't eradicate from the blood of treated patients, according to Aethlon's many stock-promoting press releases. Ebola. Gone. Hepatitis C. Vanished. HIV. Disappeared. Cancer. Eradicated.
Just think of the billions of dollars wasted each year by biotech and pharmaceutical companies on new drug research when the the solution, the cure, to so many of the world's deadliest diseases is as simple as dripping blood through a glorified, plastic-encased coffee filter. It's a wonder Aethlon is still a penny stock trading on the OTC.